NASDAQ:LIVN LivaNova Q2 2025 Earnings Report $46.13 +0.05 (+0.11%) Closing price 07/3/2025 01:00 PM EasternExtended Trading$46.10 -0.03 (-0.07%) As of 07/3/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast LivaNova EPS ResultsActual EPSN/AConsensus EPS $0.84Beat/MissN/AOne Year Ago EPSN/ALivaNova Revenue ResultsActual RevenueN/AExpected Revenue$332.20 millionBeat/MissN/AYoY Revenue GrowthN/ALivaNova Announcement DetailsQuarterQ2 2025Date7/30/2025TimeBefore Market OpensConference Call DateWednesday, July 30, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile LivaNova Earnings HeadlinesAre Options Traders Betting on a Big Move in LivaNova Stock?June 25, 2025 | msn.comLivaNova PLC (NASDAQ:LIVN) Receives $59.29 Consensus Target Price from AnalystsJune 24, 2025 | americanbankingnews.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.July 4 at 2:00 AM | Brownstone Research (Ad)LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant DepressionJune 6, 2025 | uk.finance.yahoo.comCORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant EpilepsyJune 6, 2025 | finance.yahoo.comCORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant EpilepsyJune 5, 2025 | businesswire.comSee More LivaNova Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LivaNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LivaNova and other key companies, straight to your email. Email Address About LivaNovaLivaNova (NASDAQ:LIVN) is a global medical technology company specializing in cardiovascular and neuromodulation solutions. Through its Cardiopulmonary segment, LivaNova offers a comprehensive portfolio of products designed for use in cardiac surgery and extracorporeal circulation. Key offerings include heart-lung machines, oxygenators, autotransfusion systems and proprietary mechanical circulatory support devices that aid clinicians in complex procedures such as cardiopulmonary bypass and extracorporeal membrane oxygenation (ECMO). In its Neuromodulation segment, LivaNova develops and markets the VNS Therapy System, an implantable device that delivers targeted vagus nerve stimulation for the treatment of drug-resistant epilepsy and depression. The company’s neuromodulation therapies build on decades of clinical research, providing physicians with an alternative approach to patients who have not responded adequately to pharmaceuticals. Formed in 2015 through the merger of Sorin Group and Cyberonics, LivaNova combines a rich heritage of innovation dating back to the 1950s with a forward-looking focus on next-generation medical technologies. Headquartered in London, the company maintains research, development and manufacturing operations across Europe, North America and the Asia-Pacific region, serving customers in over 100 countries. Under the leadership of President and CEO Tony Milner, LivaNova continues to expand its global footprint and invest in clinical studies and device enhancements. The company’s strategic priorities include broadening its product portfolio, strengthening regulatory partnerships and driving adoption of its advanced therapies to improve patient outcomes worldwide.Written by Jeffrey Neal JohnsonView LivaNova ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
